Level C· Early human research exploring benefitsCase Report / SeriesEurope PMCOpen access

Case Report: A rare case of over 45 years' survival in a patient with tonsillar adenoid cystic carcinoma

Wang M., Ma T., Zhao Y., Zhang S., Wang X., Yang G.

Case Report / Series on Systemic / IV, published in Front Oncol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Front Oncol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42311271
PMCID
PMC13268913
DOI
10.3389/fonc.2026.1824507

Abstract (original English)

Tonsillar adenoid cystic carcinoma (TACC) is an extremely rare malignancy with an unpredictable clinical course. We report an unusual case of TACC with a 47-year disease trajectory, characterized by prolonged indolent behavior followed by late and relatively rapid clinical progression. The patient was initially diagnosed with left tonsillar ACC in 1977 after presenting with dysphagia and underwent tonsillectomy followed by postoperative radiotherapy. A local recurrence involving the left soft palate occurred in 1996-1997 and was treated with surgical resection and tongue flap reconstruction, after which the disease remained clinically stable for many years. In 2018, recurrent ACC of the soft palate was confirmed in the radical resection specimen, and the patient underwent radical resection via a mandibulotomy approach followed by reconstruction and adjuvant concurrent chemoradiotherapy. Molecular profiling of the available 2018 recurrent soft palate lesion revealed NOTCH2 copy number gain and structural variants involving MTOR and SPEN. Regional cervical lymph node metastasis was confirmed in 2022, followed by intracranial disease progression in 2023. The patient died in 2024 from complications of progressive intracranial and systemic metastases. To our knowledge, this represents one of the longest documented clinical courses of TACC with integrated genomic analysis. This case

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research